Deals and Financings
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
In this edition of Device Week, Medtech Insight’s Catherine Longworth chats to Marion Webb about two new major partnerships signed in the diabetes sector, and finds out more about ResMed’s growth strategy.
Latest From Deals
Abbott signed a deal with Tandem Diabetes Care to develop diabetes solutions combining Abbott's glucose-sensing technology with Tandem's insulin delivery systems. See what Tandem's CEO and president, John Sheridan, said about the partnership here.
Abbott signed a deal with Tandem Diabetes Care to develop diabetes solutions to combine Abbott's glucose-sensing technology with Tandem's insulin delivery systems.
Abbott signed a deal with Omada Health to integrate Abbott's FreeStyle Libre with Omada's health coaching platform.
Diagnostic imaging agent company Lantheus Holdings will acquire Progenics Pharmaceuticals, the developer of radiotherapeutics and imaging agents to treat cancer, in an all-stock deal announced last week. See what Lantheus CEO Mary Anne Heino said about the deal here.
Lantheus says the all-stock drug-diagnostics deal brings together complementary portfolios of ultrasound and radiopharmaceutical diagnostics with oncology therapeutics.
UK robotics firm CMR Surgical landed $240m in a Series C financing round, which will propel its Versius robotic surgery system onto the market. See what CMR Surgical's CEO, Martin Frost, said about it here.
UK robotics firm CMR Surgical has landed $240m from investors as it prepares to launch its robotic surgery system in Europe and India. The Series C raise is Europe’s largest private financing round in the medical technology sector to date.
Abbott and Sanofi are partnering up to develop a new connected diabetes device. The non exclusive collaboration will combine Abbott’s FreeStyle Libre continuous glucose monitoring system with Sanofi’s connected insulin pens and software currently under development.
The companies signed a deal to allow Novo Nordisk’s smart insulin pens to share insulin dosing data with Medtronic’s continuous glucose monitoring devices. Novo Nordisk's smart insulin pens are already compatible with all other major brands of continuous glucose monitors.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.